Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

        News & Events for Human Drugs

From Our Perspective Home
          Drugs
          News & Events for Human Drugs
          From Our PerspectiveNews & Events for Human Drugs From Our Perspective
  	
        Share
    Post
    Linkedin

    Email
    PrintFDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development

*By: Cassandra L. Taylor, public health advisor, Office of the Center Director, Center for Drug Evaluation and Research (CDER) and Schuyler Pruyn, project manager, Office of Executive Programs, CDER*

FDA has a long history of reviewing clinical research for cannabis (such as marijuana and hemp) and cannabis-derived products (such as cannabidiol or CBD). Since the early 1970s, FDA has received more than 800 investigational new drug applications (INDs) for, and pre-investigational new drug applications (pre-INDs) related to cannabis and cannabis-derived products (CCDP). Over the last 10 years, there has been increased interest in studying CCDPs as medical treatment options. We have received double the number of IND and pre-IND applications during this time. We also have seen increased clinical research of new types of cannabis products and routes of administration (ROA), which is the way the drug is administered in the body.

More with Cassandra L. Taylor and Schuyler Pruyn



Previous From Our Perspectives

2023

FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development
	Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products
	CDER Takes Measures to Tackle Stimulant Use Disorder
	CDER collaborates with global regulators on pharmaceutical quality assessments and inspections
	CDER’s Efforts to Expand Opioid Disposal Options
	FDA actions to continue to ensure the safety of the nation’s drug supply
	CDER Continues to Advance Rare Disease Drug Development with New Efforts, Including the Accelerating Rare Disease Cures (ARC) Program
	CDER’s Continued Efforts to Widen Naloxone Access
	Risk Evaluation and Mitigation Strategies (REMS), Part 2 - Implementation: Challenges and Opportunities
	A Two-Part Series: Risk Evaluation and Mitigation Strategies (REMS) Program2022

FDA’s Role in Helping a Critical Medical Isotope Meet Sufficient Supply in the US for First Time
	FDA Issues Draft Guidances on Real-World Evidence, Prepares to Publish More in Future2021

50 Years of Progress in Treating Patients with Cancer
	FDA Holds Workshop to Discuss the Safe Use of Benzodiazepines
	FDA Approval Demonstrates the Role of Real-World Evidence in Regulatory Decision-Making on Drug Effectiveness
	CURE ID Moves to Automated Data Collection in Light of COVID Pandemic
	FDA’s Decision to Approve New Treatment for Alzheimer’s Disease
	Generic Drugs in the 21st Century: FDA’s Actions Create Transparency and Value for Complex Generic Product Development
	FDA and Duke-Margolis Host Workshop on Scientific and Ethical Considerations for Including Pregnant People in Clinical Trials2020

The Orange Book at 40: A valued FDA resource continually enhanced by user input
	Bad Ad Program at 10, Educating Healthcare Providers to Recognize and Report Potentially False or Misleading Prescription Drug Promotion

                                                                                  Content current as of:
      01/16/2024
                  
                   
Regulated Product(s)
		 DrugsFrom Our Perspective
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop